MMP2 and MMP9 matrix metalloproteinases due to their ability to destroy basement membranes collagen and remodeling extracellular matrix (ECM) in the micro-environment of blood progenitor cells in the bone marrow play the important role in hematopoiesis. Displacement of normal hematopoiesis and dissemination of malignant cells in proliferative diseases of blood is also accompanied by catalytic ECM rearrangement. However, it is not known exactly how activity of MMP2 and MMP9 changes in various forms of leukemia and how it is affected by chemotherapeutic drugs. The aim of this study was to determine the influence of anthracycline antibiotics (daunorubicin and adriablastin) on MMP2 and MMP9 activity in blood plasma of patients with acute myeloid leukemia, chronic lymphocytic leukemia and multiple myeloma. It was established that proMMP9 activity was significantly reduced (0,03 ± 0,01 rel. u.) in patients with acute myeloid leukemia before the treatment, however, after chemotherapy, it increased approximately 7 times. Chronic lymphocytic leukemia and multiple myeloma were accompanied by significant increase of MMP9 activity. Application of daunorubicin led to decrease of proMMP9 activity (0,25 ± 0,10 rel. u.) in patients with chronic lymphocytic leukemia. ProMMP9 activity was significantly reduced (16 times) and that of MMP9 increased in case of multiple myeloma. In studying of MMP2 activity it did not significantly change. The conclusion is that the ratio of proMMP9/MMP9 can be used as the additional criterion for monitoring the effectiveness of chemotherapy of proliferative diseases of blood.
Updates on Hematologic Malignancies in the Older Adult: Focus on Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, and Multiple Myeloma
